Angiopoietin-TIE2 Signalling: Stabilising and Destabilising Vessels

The Receptor and Its Ligands

TIE2 (encoded by TEK) is a receptor tyrosine kinase expressed mainly on endothelial cells, with lower levels on some pericytes and monocytes. Its ligands, the angiopoietins, are produced largely by perivascular and stromal cells.

Angiopoietin-1 (ANG1) is a strong TIE2 activator; angiopoietin-2 (ANG2) is context-dependent and often acts to block ANG1.

ANG1: Keeping Vessels Quiet

ANG1 signalling through TIE2 promotes endothelial survival, tightens cell-cell junctions and supports pericyte coverage. The overall effect is a stable, low-permeability, mature vessel.

This is why ANG1-TIE2 activity is associated with vessel normalisation and reduced leakiness.

ANG2: Loosening Vessels

ANG2 is stored in endothelial Weibel-Palade bodies and released rapidly on activation. By competing with ANG1 at TIE2, it destabilises vessels, allowing them to sprout in the presence of VEGF or to regress in its absence.

In tumours and in inflammation ANG2 is strongly upregulated, promoting an unstable, permeable vasculature and helping recruit pro-angiogenic monocytes.

Targeting the Pathway

Because ANG2 rises when VEGF is blocked and contributes to escape, dual inhibition has been tested. The bispecific antibody faricimab targets both VEGFA and ANG2 and is approved in retinal vascular disease; in oncology, agents such as trebananib (an angiopoietin-neutralising peptibody) have shown limited benefit.

Overall, angiopoietin-targeted drugs have been more successful in eye disease than in cancer so far.

Interpretation Notes

Somatic activating TEK (TIE2) mutations cause venous malformations, a benign vascular anomaly distinct from tumour angiogenesis.

Angiopoietin levels are studied as candidate biomarkers but are not used for treatment selection in routine oncology practice.

Key Takeaways

• ·TIE2 controls vessel stability; ANG1 activates it, ANG2 usually antagonises it.
• ·ANG1 makes vessels quiescent and mature; ANG2 destabilises them for remodelling.
• ·Tumour ANG2 upregulation promotes unstable vessels and anti-VEGF escape.
• ·Dual VEGF/ANG2 blockade is established in eye disease, less so in cancer.